Linkedin
RLS logo_header
Linkedin

Guardant Health and Pfizer to Develop and Commercialize New Cancer Therapies Using Guardant Infinity Smart Liquid Biopsy Platform

“Guardant Health, Inc., a leading precision oncology company, today announced a strategic collaboration with Pfizer, Inc., to support the development and commercialization of Pfizer’s oncology portfolio using the Guardant Infinity™ smart liquid biopsy platform. Under the multi-year collaboration agreement, Guardant and Pfizer aim to utilize Guardant’s portfolio of liquid biopsy tests in Pfizer’s global clinical studies, and evaluate the clinical utility of (a) circulating tumor DNA (ctDNA) level as a surrogate endpoint to monitor therapy response and (b) related blood-based epigenomic analyses.”

Read the full story on "Guardant Health and Pfizer to Develop and Commercialize New Cancer Therapies Using Guardant Infinity Smart Liquid Biopsy Platform"

Share:

More News

FDA Grants Fast Track Designation for TRE-515 in Combination with KRAS G12C Inhibitors for the Treatment of NSCLC

“Fast Track designation in lung cancer represents an important milestone for TRE-515 and further validates our strategy of combining dCK inhibition with targeted cancer therapies,” said Dr. Ken Schultz, Trethera Chairman and CEO. “KRAS G12C inhibitors have transformed the NSCLC treatment landscape, but resistance and incomplete responses remain major challenges.

Ligand and AvenCell Therapeutics Enter Financing Agreement to Advance Pipeline of Next-Generation CAR-T Therapies for Up to $47 Million

“AvenCell has built a differentiated cell therapy platform that brings together CRISPR-engineered allogeneic CAR-T technology with a unique switchable CAR approach designed to provide greater control over CAR-T activity,” said Todd Davis, CEO of Ligand. “We believe the combination of these technologies, together with the encouraging clinical data generated to

First Patient Enrolled in Global Ph 3 Trial of Cadonilimab vs Nivolumab in 1L Gastric Cancer

“Advanced gastric cancer is characterized by substantial biological and clinical heterogeneity. Previous studies have shown that the magnitude of benefit from PD-1 inhibitor therapy is closely associated with PD-L1 expression, and that there remains room to further improve outcomes, particularly in patients with low PD-L1 expression. How to broaden the

Giredestrant combination significantly improved PFS in ER-positive advanced breast cancer in Ph 3 evERA; data published in The NEJM

“The evERA results represent an important step forward for people with ER-positive advanced breast cancer and underscore the potential for giredestrant to help address the challenge of disease progression in this setting,” said Levi Garraway, MD, PhD, Roche’s Chief Medical Officer and Head of Global Product Development. “Together with the